Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
62%51%40%Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 21 • YES 51.0%May 22 • YES 52.2%May 23 • YES 46.4%May 24 • YES 54.7%
Revolution Medicines, Inc. ($RVMD)
No stock closeNo stock close$142.9$115.8$88.81Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24Apr 6 • RVMD $95.36Apr 7 • RVMD $96.29Apr 8 • RVMD $96.75Apr 9 • RVMD $96.22Apr 10 • RVMD $96.43Apr 13 • RVMD $136.3
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
4/13/26
Study Completion
12/1/27
Sponsor
Revolution Medicines, Inc.
Ticker
$RVMD
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
500
NCT
NCT06625320
Trial Description
Daraxonrasib is being tested against standard chemotherapy in previously treated metastatic pancreatic cancer, measuring time without worsening and survival.